Aardvark Therapeutics vs Artelo Biosciences
AARD and ARTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AARD and ARTL compare
Aardvark Therapeutics is the larger company, worth 22 times as much as Artelo Biosciences ($25.2M against $1.1M).
Aardvark Therapeutics scores higher on the StockData Score (6 against 2 for Artelo Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AARD | ARTL |
|---|---|---|
| Size and price | ||
| Market cap | $25.2M | $1.1M |
| Share price | $1.15 | $1.68 |
| Change, 1 year | −88.4% | −96.6% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | 5.01 | −2.63 |
| Employees | 40 | 5 |
| StockData Score | ||
| Total score | 6 (better) | 2 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× | 0.2× (better) |
| Profitability | ||
| Return on equity | −66.0% (better) | −706% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −48.5× |
| Current ratio | 12.63 (better) | 3.00 |
| Altman Z-score | −2.25 (better) | −19.48 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −1351% |
| Shareholder yield | 0.00% (better) | −1351% |
| Ownership | ||
| Held by institutions | 43.6% | 1.9% |
| Held by insiders | 41.9% | 57.0% |
| Insider net buying, 12 months | −$250K | – |
| Short interest, % of float | 8.2% | 9.6% |
Go deeper
- AARD stock overview
- AARD income statement
- AARD valuation and score
- ARTL stock overview
- ARTL income statement
- ARTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.